(19)
(11) EP 0 933 995 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.01.2005 Bulletin 2005/03

(45) Mention of the grant of the patent:
17.11.2004 Bulletin 2004/47

(21) Application number: 97940974.5

(22) Date of filing: 10.09.1997
(51) International Patent Classification (IPC)7: A61K 38/18, A61K 31/28
// (A61K38/18, 31:28, A61P35:00)
(86) International application number:
PCT/US1997/015966
(87) International publication number:
WO 1998/010650 (19.03.1998 Gazette 1998/11)

(54)

METHOD OF TREATING ENDOTHELIAL INJURY

VERFAHREN ZUR BEHANDLUNG VON ENDOTHELIALEN VERLETZUNGEN

METHODE DE TRAITEMENT DES LESIONS ENDOTHELIALES

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 11.09.1996 US 712358

(43) Date of publication of application:
11.08.1999 Bulletin 1999/32

(73) Proprietor: EAST CAROLINA UNIVERSITY
Greenville, NC 27858-4353 (US)

(72) Inventors:
  • ANAGNOSTOU, Athanasius, A.
    Greenville, NC 27858 (US)
  • SIGOUNAS, George
    Greenville, NC 27858 (US)

(74) Representative: Harrison Goddard Foote 
Belgrave Hall Belgrave Street
Leeds LS2 8DD
Leeds LS2 8DD (GB)


(56) References cited: : 
   
  • DATABASE WPI Section Ch, Week 199020 Derwent Publications Ltd., London, GB; Class B04, AN 1990-151821 XP002204207 & JP 02 096535 A (CHUGAI PHARM CO LTD), 9 April 1990 (1990-04-09)
  • BUKOWSKI R. ET AL.: "Phase IV evaluation of clinical outcomes of PROCRIT (Epoetin alfa) in anemic cancer patients receiving chemotherapy" BLOOD, JOURNAL OF THE AMERICAN SOCIETY OF HEMATOLOGY, vol. 84, no. 10 Suppl. 1, December 1994 (1994-12), page 129A XP001079959
  • TAYLOR J E ET AL: "Effect of nifedipine on changes in fibrinogen and von Willebrand factor in haemodialysis patients treated with recombinant human erythropoietin." BLOOD COAGULATION & FIBRINOLYSIS: AN INTERNATIONAL JOURNAL IN HAEMOSTASIS AND THROMBOSIS. ENGLAND APR 1995, vol. 6, no. 2, April 1995 (1995-04), pages 100-104, XP001085060 ISSN: 0957-5235
  • TAYLOR J E ET AL: "Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients." KIDNEY INTERNATIONAL. UNITED STATES JUL 1993, vol. 44, no. 1, July 1993 (1993-07), pages 182-190, XP001085030 ISSN: 0085-2538
  • REINHART W H: "Shear-dependence of endothelial functions." EXPERIENTIA. SWITZERLAND 15 FEB 1994, vol. 50, no. 2, 15 February 1994 (1994-02-15), pages 87-93, XP001085086 ISSN: 0014-4754
  • TRENDS IN EXPERIMENTAL AND CLINICAL MEDICINE, 1993, Vol. 3, CAZZOLA M., "Erythropoietin: Biology and Clinical Applications", pages 344-361.
  • AM. J. HYPERTEN., 1996, Vol. 9, No. 5, KURIYAMA et al., "Evidence for Amelioration of Endothelial Cell Dysfunction by Erythropoietin Therapy in Predialysis Patients", pages 426-431.
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).